PCM
AXDX

PenderFund Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

PenderFund Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-46,526
Closed -$3.44M – 155
2021
Q3 		$3.44M Buy
+46,526
New +$3.03M 0.9% 38

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

PenderFund Capital Management's AXDX Position: Q4 2021 in Review

PenderFund Capital Management sold out of Accelerate Diagnostics (AXDX) in Q4 2021, closing a stake of 46,526 shares — an estimated $3.44M sold.

PenderFund Capital Management first reported a position in AXDX in Q3 2021 and held it in 1 quarter. The position peaked at $3.44M in Q3 2021. 107 funds tracked by Wall St. Rank hold AXDX as of Q4 2021.

  • PenderFund Capital Management reported no remaining Accelerate Diagnostics position as of Q4 2021 after selling out during the quarter.
  • PenderFund Capital Management sold 46,526 Accelerate Diagnostics shares in Q4 2021, an estimated $3.44M.
  • PenderFund Capital Management first reported a position in Accelerate Diagnostics in Q3 2021 and held it in 1 quarter.
  • PenderFund Capital Management's Accelerate Diagnostics position peaked at $3.44M in Q3 2021.
  • 107 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2021.

Based on PenderFund Capital Management's 13F filing for Q4 2021, filed 16 Feb 2022.